secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monte Rosa Therapeutics, Inc. (GLUE)
CIK:        0001826457
Form:       8-K
Filed at:   2024-12-05T23:59:59+00:00
Accession:  0000950170-24-133525
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monte Rosa sets RP2D for MRT-2359 at 0.5 mg/day 21/7 schedule; safety, PD data positive
--------------------------------------------------------------------------------

- RP2D selected: 0.5 mg daily on 21-days-on/7-days-off schedule based on favorable safety and ~60% GSPT1 degradation.
- No hypotension, cytokine release syndrome, or clinically significant hypocalcemia observed at any dose.
- Doses ≥1.5 mg/day on 5/9 schedule exceeded MTD; thrombocytopenia was DLT; 0.5 and 1 mg were tolerable.
- Combination safety assessments started: MRT-2359 + enzalutamide in prostate cancer and + fulvestrant in breast cancer.
- Updated biomarker and activity data from Phase 1/2 study expected in Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826457/000095017024133525/0000950170-24-133525-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826457/000095017024133525/glue-20241205.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-133525

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer